Page 10 - நைஜீரியன் நிறுவனம் ஆஃப் மருத்துவ ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Punch Newspapers Sections IT is heartening that efforts are ongoing to develop a vaccine for Lassa fever. An American biotechnology company, INOVIO, which is spearheading the research, noted that the first participant in Lassa vaccine trial had been dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever. The clinical trial in progress in Ghana is reportedly focusing on offering precisely-designed DNA medicines to treat and protect people from infectious diseases and cancer. Lassa fever, according to the United States Centres for Disease Control and Prevention, is an animal-borne, or zoonotic, acute viral illness. It is endemic in parts of West Africa, including Sierra Leone, Liberia, Guinea and Nigeria. The illness was discovered in 1969 and is named after the town in Nigeria where the first cases occurred. The CDC says an estimated 100,000 to 300,000 infections of Lassa fever occur annually, with approximately 5,000 deaths. The World Health O

Abuja federal capital territoryNigeria generalUnited statesFederal capital territoryGreater accraSierra leoneChikwe ihekweazuNoguchi memorial institute for medical researchNigeria centre for diseaseCoalition for epidemic preparedness innovationsNigerian institute of medical researchWorld health organisationUnited states centresDisease controlWest africaNoguchi memorial institute